SAN DIEGO, June 15, 2021 /PRNewswire/ -- Prometheus Laboratories, Inc. ("Prometheus"), a leader in precision healthcare, announces the execution of an agreement with MultiPlan, a trusted partner to ...

SAN DIEGO, CA / ACCESSWIRE / May 9, 2024 / Prometheus Laboratories Inc. ("Prometheus"), a leader in precision medicine for immune-mediated diseases, announced the execution of provider agreements with ...

Prometheus Laboratories announced the launch of its monitoring test, PROMETHEUS Anser IFX, which measures infliximab (Remicade; Janssen Biotech) and infliximab antibody levels in one sample to be used ...

SAN DIEGO, March 28, 2017 /PRNewswire/ -- Prometheus Laboratories Inc.—a Nestlé Health Science company—announces the launch of IBcause™, an all-in-one convenient test that evaluates a unique ...

SAN DIEGO, July 31, 2012 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the market launch of its proprietary new generation monitoring ...

The MarketWatch News Department was not involved in the creation of this content. New Therapeutic Drug Monitoring Test for Interleukin--23 Inhibitor SAN DIEGO, CA / ACCESS Newswire / April 1, 2025 / ...

SAN DIEGO, CA / ACCESS Newswire / August 27, 2025 / Prometheus Laboratories Inc. ("Prometheus"), a leader in precision healthcare, today announced a collaboration with Celltrion USA, Inc. ("Celltrion ...

When dosing is optimized, biologics such as IFX are highly effective for managing CD and UC. Anser IFX testing uses a drug-tolerant homogeneous mobility shift assay (HMSA) to provide clinicians ...

Prometheus Laboratories has been a leader in IBD patient care solutions for 30 years. Our continuum of tests empowers providers to diagnose, treat and help get IBD patients into remission faster with ...